Rhumbline Advisers boosted its holdings in shares of Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report) by 21.6% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 132,569 shares of the company’s stock after acquiring an additional 23,565 shares during the quarter. Rhumbline Advisers owned 0.16% of Beam Therapeutics worth $3,106,000 as of its most recent SEC filing.
Other large investors also recently bought and sold shares of the company. Russell Investments Group Ltd. boosted its holdings in Beam Therapeutics by 4.4% during the 1st quarter. Russell Investments Group Ltd. now owns 143,828 shares of the company’s stock valued at $4,752,000 after acquiring an additional 6,102 shares during the period. Vanguard Group Inc. raised its position in Beam Therapeutics by 5.8% during the 1st quarter. Vanguard Group Inc. now owns 7,578,768 shares of the company’s stock valued at $250,402,000 after purchasing an additional 413,892 shares in the last quarter. UBS Group AG raised its position in Beam Therapeutics by 118.2% during the 4th quarter. UBS Group AG now owns 260,500 shares of the company’s stock valued at $7,091,000 after purchasing an additional 141,102 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in Beam Therapeutics by 34.6% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 223,929 shares of the company’s stock valued at $6,782,000 after purchasing an additional 57,554 shares in the last quarter. Finally, Bellevue Group AG raised its position in Beam Therapeutics by 71.7% during the 1st quarter. Bellevue Group AG now owns 1,193,121 shares of the company’s stock valued at $39,421,000 after purchasing an additional 498,300 shares in the last quarter. Hedge funds and other institutional investors own 99.68% of the company’s stock.
Insider Buying and Selling
In other Beam Therapeutics news, CEO John M. Evans sold 60,000 shares of the stock in a transaction that occurred on Thursday, June 27th. The stock was sold at an average price of $24.50, for a total transaction of $1,470,000.00. Following the completion of the transaction, the chief executive officer now owns 998,343 shares of the company’s stock, valued at $24,459,403.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 4.20% of the stock is currently owned by insiders.
Analysts Set New Price Targets
Get Our Latest Stock Analysis on Beam Therapeutics
Beam Therapeutics Price Performance
Shares of NASDAQ:BEAM opened at $25.58 on Wednesday. The business’s 50-day moving average is $26.29 and its 200 day moving average is $26.63. The firm has a market capitalization of $2.11 billion, a P/E ratio of -14.37 and a beta of 1.86. Beam Therapeutics Inc. has a 1 year low of $16.95 and a 1 year high of $49.50.
Beam Therapeutics (NASDAQ:BEAM – Get Free Report) last issued its earnings results on Tuesday, August 6th. The company reported ($1.11) EPS for the quarter, topping analysts’ consensus estimates of ($1.13) by $0.02. Beam Therapeutics had a negative return on equity of 16.22% and a negative net margin of 40.56%. The firm had revenue of $11.80 million for the quarter, compared to the consensus estimate of $14.18 million. During the same quarter in the prior year, the business earned ($1.08) earnings per share. The company’s revenue was down 41.3% compared to the same quarter last year. On average, analysts expect that Beam Therapeutics Inc. will post -4.6 EPS for the current year.
Beam Therapeutics Profile
Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.
See Also
- Five stocks we like better than Beam Therapeutics
- With Risk Tolerance, One Size Does Not Fit All
- Galmed Pharmaceuticals Surges 400%: What’s Behind the Explosion?
- What is the S&P/TSX Index?
- Gold Hits New All-Time Highs: 3 Stocks to Ride the Surge
- NYSE Stocks Give Investors a Variety of Quality OptionsĀ
- Intel: Why It’s Time to Reconsider This Beaten-Down Chipmaker
Want to see what other hedge funds are holding BEAM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Beam Therapeutics Inc. (NASDAQ:BEAM – Free Report).
Receive News & Ratings for Beam Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beam Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.